Which has higher earnings and valuation, ANIX or KMDA?

Kamada has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anixa Biosciences $210K 494.10 -$10.93M -$0.31 N/A Kamada $180.46M 2.64 $20.20M $0.38 21.76

Is ANIX or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Anixa Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Kamada 11.60% 8.37% 5.85%

Does the media prefer ANIX or KMDA?

In the previous week, Anixa Biosciences had 2 more articles in the media than Kamada. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for Kamada. Anixa Biosciences' average media sentiment score of 0.00 equaled Kamada'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANIX or PBYI?

In the previous week, Puma Biotechnology had 10 more articles in the media than Anixa Biosciences. MarketBeat recorded 14 mentions for Puma Biotechnology and 4 mentions for Anixa Biosciences. Puma Biotechnology's average media sentiment score of 0.43 beat Anixa Biosciences' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, QTTB or ANIX?

Q32 Bio has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 7.09 $29.82M $3.00 4.27 Anixa Biosciences $210K 494.10 -$10.93M -$0.31 N/A

Is QTTB or ANIX more profitable?

Q32 Bio's return on equity of 50.17% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Anixa Biosciences N/A -71.12% -62.88%

Does the media prefer QTTB or ANIX?

In the previous week, Anixa Biosciences had 1 more articles in the media than Q32 Bio. MarketBeat recorded 4 mentions for Anixa Biosciences and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.43 beat Anixa Biosciences' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANIX or PRLD more profitable?

Anixa Biosciences' return on equity of -71.12% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Prelude Therapeutics N/A -75.35% -44.39%

Does the media refer more to ANIX or PRLD?

In the previous week, Anixa Biosciences had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for Prelude Therapeutics. Anixa Biosciences' average media sentiment score of 0.00 beat Prelude Therapeutics' score of -0.17 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANIX or OCGN more profitable?

Anixa Biosciences' return on equity of -71.12% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Ocugen N/A -127,987.80% -115.95%

Does the media refer more to ANIX or OCGN?

In the previous week, Ocugen had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 7 mentions for Ocugen and 4 mentions for Anixa Biosciences. Ocugen's average media sentiment score of 0.66 beat Anixa Biosciences' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anixa Biosciences (ANIX) Competitors

$3.05 -0.08 (-2.56%)

As of 09/3/2026 04:00 PM Eastern

Compare

ANIX vs. KMDA, PBYI, QTTB, PRLD, and OCGN

Should you buy Anixa Biosciences stock or one of its competitors? Anixa Biosciences's main competitors and comparable companies include Kamada (KMDA), Puma Biotechnology (PBYI), Q32 Bio (QTTB), Prelude Therapeutics (PRLD), and Ocugen (OCGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anixa Biosciences compare to Kamada?

Anixa Biosciences (NASDAQ:ANIX) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

In the previous week, Anixa Biosciences had 2 more articles in the media than Kamada. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for Kamada. Anixa Biosciences' average media sentiment score of 0.00 equaled Kamada'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	494.10	-$10.93M	-$0.31	N/A
Kamada	$180.46M	2.64	$20.20M	$0.38	21.76

Anixa Biosciences has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Kamada has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 178.69%. Kamada has a consensus price target of $13.00, indicating a potential upside of 57.19%. Given Anixa Biosciences' higher probable upside, equities analysts plainly believe Anixa Biosciences is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has a net margin of 11.60% compared to Anixa Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Kamada	11.60%	8.37%	5.85%

Summary

Kamada beats Anixa Biosciences on 10 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Puma Biotechnology?

Anixa Biosciences (NASDAQ:ANIX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Puma Biotechnology has a net margin of 11.50% compared to Anixa Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Puma Biotechnology	11.50%	20.76%	13.22%

In the previous week, Puma Biotechnology had 10 more articles in the media than Anixa Biosciences. MarketBeat recorded 14 mentions for Puma Biotechnology and 4 mentions for Anixa Biosciences. Puma Biotechnology's average media sentiment score of 0.43 beat Anixa Biosciences' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 178.69%. Puma Biotechnology has a consensus target price of $6.00, indicating a potential downside of 36.24%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Anixa Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	494.10	-$10.93M	-$0.31	N/A
Puma Biotechnology	$228.40M	2.13	$31.11M	$0.52	18.10

Summary

Puma Biotechnology beats Anixa Biosciences on 11 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Q32 Bio has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	7.09	$29.82M	$3.00	4.27
Anixa Biosciences	$210K	494.10	-$10.93M	-$0.31	N/A

In the previous week, Anixa Biosciences had 1 more articles in the media than Q32 Bio. MarketBeat recorded 4 mentions for Anixa Biosciences and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.43 beat Anixa Biosciences' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio's return on equity of 50.17% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Anixa Biosciences	N/A	-71.12%	-62.88%

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Q32 Bio presently has a consensus price target of $31.00, indicating a potential upside of 142.19%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 178.69%. Given Anixa Biosciences' higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Q32 Bio beats Anixa Biosciences on 11 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Prelude Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Anixa Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 178.69%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 46.03%. Given Anixa Biosciences' higher probable upside, equities research analysts clearly believe Anixa Biosciences is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Anixa Biosciences had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Anixa Biosciences and 2 mentions for Prelude Therapeutics. Anixa Biosciences' average media sentiment score of 0.00 beat Prelude Therapeutics' score of -0.17 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences' return on equity of -71.12% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Anixa Biosciences has higher earnings, but lower revenue than Prelude Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	494.10	-$10.93M	-$0.31	N/A
Prelude Therapeutics	$12.14M	34.51	-$99.50M	-$0.73	N/A

Summary

Anixa Biosciences beats Prelude Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Anixa Biosciences compare to Ocugen?

Anixa Biosciences (NASDAQ:ANIX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Ocugen had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 7 mentions for Ocugen and 4 mentions for Anixa Biosciences. Ocugen's average media sentiment score of 0.66 beat Anixa Biosciences' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences has higher earnings, but lower revenue than Ocugen. Anixa Biosciences is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	494.10	-$10.93M	-$0.31	N/A
Ocugen	$4.41M	103.81	-$67.85M	-$0.26	N/A

Anixa Biosciences' return on equity of -71.12% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Ocugen	N/A	-127,987.80%	-115.95%

Anixa Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market.

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 178.69%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 603.70%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Ocugen beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$106.49M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-9.84	12.66	273.29	25.38
Price / Sales	494.10	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	7.26	16.29	12.89	6.14
Net Income	-$10.93M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-12.36%	0.34%	0.60%	-0.27%
1 Month Performance	-10.56%	8.52%	5.73%	0.68%
1 Year Performance	2.69%	52.66%	25.35%	14.84%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	3.7424 of 5 stars	$3.05 -2.6%	$8.50 +178.7%	+2.0%	$106.49M	$210K	N/A	5	Upcoming Earnings
KMDA Kamada	4.689 of 5 stars	$8.30 +0.5%	$13.00 +56.6%	+18.7%	$477.29M	$191.85M	21.84	360
PBYI Puma Biotechnology	1.1119 of 5 stars	$9.08 -1.7%	$6.00 -33.9%	+83.4%	$468.71M	$228.40M	17.46	200	Trending News Analyst Revision
QTTB Q32 Bio	3.2268 of 5 stars	$15.51 -4.0%	$31.00 +99.9%	+648.5%	$461.73M	$53.74M	5.17	39
PRLD Prelude Therapeutics	1.7048 of 5 stars	$5.78 -8.8%	$7.67 +32.6%	+330.3%	$461.24M	$12.14M	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. KMDA, PBYI, QTTB, PRLD, and OCGN

How does Anixa Biosciences compare to Kamada?

Summary

How does Anixa Biosciences compare to Puma Biotechnology?

Summary

How does Anixa Biosciences compare to Q32 Bio?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Summary

How does Anixa Biosciences compare to Ocugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. KMDA, PBYI, QTTB, PRLD, and OCGN

How does Anixa Biosciences compare to Kamada?

Does the media prefer ANIX or KMDA?

Do insiders & institutionals have more ownership in ANIX or KMDA?

Which has higher earnings and valuation, ANIX or KMDA?

Which has more risk and volatility, ANIX or KMDA?

Do analysts recommend ANIX or KMDA?

Is ANIX or KMDA more profitable?

Summary

How does Anixa Biosciences compare to Puma Biotechnology?

Do institutionals and insiders believe in ANIX or PBYI?

Is ANIX or PBYI more profitable?

Does the media refer more to ANIX or PBYI?

Which has more volatility & risk, ANIX or PBYI?

Do analysts prefer ANIX or PBYI?

Which has higher earnings & valuation, ANIX or PBYI?

Summary

How does Anixa Biosciences compare to Q32 Bio?

Which has more risk & volatility, QTTB or ANIX?

Which has stronger earnings & valuation, QTTB or ANIX?

Does the media prefer QTTB or ANIX?

Is QTTB or ANIX more profitable?

Do institutionals & insiders have more ownership in QTTB or ANIX?

Do analysts recommend QTTB or ANIX?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Which has more risk and volatility, ANIX or PRLD?

Do analysts recommend ANIX or PRLD?

Do institutionals and insiders believe in ANIX or PRLD?

Does the media refer more to ANIX or PRLD?

Is ANIX or PRLD more profitable?

Which has preferable earnings & valuation, ANIX or PRLD?

Summary

How does Anixa Biosciences compare to Ocugen?

Does the media refer more to ANIX or OCGN?

Which has stronger earnings and valuation, ANIX or OCGN?

Is ANIX or OCGN more profitable?

Which has more risk & volatility, ANIX or OCGN?

Do analysts recommend ANIX or OCGN?

Do insiders and institutionals believe in ANIX or OCGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools